Technology | 2019.09.02
Hansa Biopharma: Issue and Re-purchase of Class C Shares for Incentive Programme
LUND, Sweden, Sept. 2, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that by virtue of the authorisation by the annual general meeting held on 22 May 2019, the board of directors of Hansa Biopharma AB...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]ntive-programme-300910257.html
